Literature DB >> 4005491

The effect of trimethoprim on serum creatinine.

J Kastrup, P Petersen, R Bartram, J M Hansen.   

Abstract

The influence of trimethoprim on renal function has been investigated in two groups of volunteers, both without a history of either acute or chronic urinary tract disease. All had normal serum creatinine. They were treated with trimethoprim 200 mg bd for 14 days. In group A (median age 78 years), serum creatinine increased significantly from median 89 to 134 mumol/l (P less than 0.01) during the first week and returned to normal 1 week after termination of treatment to median 90 mumol/l (P less than 0.02). After 1 week's treatment in group B (median age 29 years), serum creatinine had increased significantly from median 87 to 107 mumol/l (P less than 0.05), remained stable in the second week and returned to the pre-treatment level 1 week after cessation of treatment: 87 mumol/l (P less than 0.05). The glomerular filtration rate determined by 51Cr-EDTA clearance did not change. There was a significant decrease in the 24-h endogenous creatinine clearance after 14 days' treatment from 111 to 87 ml/min/1.73 m2 (P less than 0.05). Our results are consistent with an age-independent reversible trimethoprim-induced inhibition of the tubular secretion of creatinine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005491     DOI: 10.1111/j.1464-410x.1985.tb06340.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  14 in total

1.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

2.  Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions.

Authors:  O Naderer; A N Nafziger; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.

Authors:  Evelyn M Brosnan; Andrew J Weickhardt; Xian Lu; Delee A Maxon; Anna E Barón; Michel Chonchol; D Ross Camidge
Journal:  Cancer       Date:  2013-11-20       Impact factor: 6.860

Review 4.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

5.  A Common Molecular Switch for H2S to Regulate Multiple Protein Targets.

Authors:  Bei-Bei Tao; Yi-Chun Zhu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  The renal effects of ALK inhibitors.

Authors:  Hassan Izzedine; Rania Kheder El-Fekih; Mark A Perazella
Journal:  Invest New Drugs       Date:  2016-07-29       Impact factor: 3.850

7.  Deterioration of kidney function by high doses of co-trimoxazole in man.

Authors:  T B Vree; M Martea; Y A Hekster; E F Termond; R Van Klaveren; J W Lammers; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

8.  Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.

Authors:  Barbara Grün; Michael K Kiessling; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Geraldine Rauch; Walter E Haefeli; David Czock
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

9.  Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.

Authors:  Ann M Ginsberg; Martino W Laurenzi; Doris J Rouse; Karl D Whitney; Mel K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

10.  The effect of acyclovir on the tubular secretion of creatinine in vitro.

Authors:  Patrina Gunness; Katarina Aleksa; Gideon Koren
Journal:  J Transl Med       Date:  2010-12-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.